Buy Tirzepatide – Research Peptide | PEPTEX
Lipidated 39-amino acid synthetic peptide. CAS 2023788-19-2. MW 4813.53 Da. Purity ≥98% by HPLC and MS. Carries a C18 fatty diacid moiety at Lys²⁶ for extended plasma half-life in solution. White to off-white lyophilised powder; reconstitute in sterile aqueous solution. Supplied in a sealed borosilicate glass vial. Intended for laboratory and research use only. Store at −20°C; protect from light and moisture.
Price: EUR | Brand: PEPTEX | In Stock | EU-wide delivery, up to 7 business days
Rating: 5/5 (546 reviews)
Customer Reviews
Marta — ★★★★
Effective but shipping to Netherlands took 8 days last time. First order arrived in 4. Product itself is consistent though.
Marta P. — ★★★★★
packaging impressed me honestly. double insulated, cold packs still frozen after 4 days in transit to Madrid. the powder dissolved perfectly. on week 6 now and eating about 40% less without trying
Daisy — ★★★★★
This is my go-to for weight management research now. Five orders in, never disappointed. Support team actually knows what they're talking about which is rare in this space.
Nicolas D. — ★★★★
Works but the GI side effects at 7.5mg were rough for me. Stayed at 5mg which is more tolerable. Results are slower but consistent. Product quality itself is fine, just wish my stomach agreed with higher doses.
Günther — ★★★★★
My husband and I both use tirzepatide from peptex. He's on 10mg, I'm on 5mg. Both seeing steady progress. The fact that you can adjust the dose with vials gives us flexibility that pens don't offer. Third order for both of us.
Available Sizes
- 10mg — 79 EUR
- 30mg — 174 EUR
- 60mg — 309 EUR
Storage Recommendations
| Condition | Temperature | Duration |
|---|---|---|
| Lyophilised | -20°C | Up to 24 months |
| Reconstituted | 2-8°C | Up to 12 weeks with Sterile Diluent Solution |
Research References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — NEJM / PubMed (2022)
- Tirzepatide versus Semaglutide in Type 2 Diabetes — NEJM / PubMed (2021)
- Efficacy of tirzepatide in type 2 diabetes (SURPASS-1 trial) — Lancet / PubMed (2021)
💬 Комментарии